Metabolic modulation of acute myocardial infarction - The ECLA glucose-insulin-potassium pilot trial

Simple item page
dc.contributor.authorDiaz, R
dc.contributor.authorPaolasso, A
dc.contributor.authorPiegas, LS
dc.contributor.authorTajer, CD
dc.contributor.authorMoreno, MG
dc.contributor.authorCorvalan, R
dc.contributor.authorIsea, JE
dc.contributor.authorRomero, G
dc.date.accessioned2024-01-10T13:14:49Z
dc.date.available2024-01-10T13:14:49Z
dc.date.issued1998
dc.description.abstractBackground-Several trials have been performed in the past using glucose, insulin, and potassium infusion (GIK) for the treatment of acute myocardial infarction (AMI). Because of continuing uncertainty about the potential role of this therapeutic intervention, we conducted a randomized trial to evaluate the impact of a GIK solution during the first hours of AMI,
dc.description.abstractMethods and Results-Four hundred seven patients with suspected AMI admitted within 24 hours of symptoms onset were enrolled. In a ratio of 2:1, 268 patients were allocated to receive GIK (high- or low-dose) and 139 to receive control. Phlebitis and serum changes in the plasma concentration of glucose or potassium were observed more often with GIK, A trend toward a nonsignificant reduction in major and minor in-hospital events was observed in patients allocated to GIK, In 252 patients (61.9%) treated with reperfusion strategies, a statistically significant reduction in mortality (relative risk [RR] 0.34; 95% CI: 0.15 to 0.78; 2P=0.008) and a consistent trend toward fewer in-hospital events in the GIK group were observed,
dc.description.abstractConclusions-Our results confirm that a metabolic modulation strategy in the first hours of an AMI is feasible, applicable worldwide, and has mild side effects. The statistically significant mortality reduction in patients who underwent a reperfusion strategy might have important implications for the management of AMI patients. It is now essential to perform a large-scale trial to reliably determine the magnitude of benefit.
dc.fechaingreso.objetodigital2024-05-16
dc.format.extent8 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1161/01.CIR.98.21.2227
dc.identifier.eissn1524-4539
dc.identifier.issn0009-7322
dc.identifier.pubmedidMEDLINE:9867443
dc.identifier.urihttps://doi.org/10.1161/01.CIR.98.21.2227
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78444
dc.identifier.wosidWOS:000077072700003
dc.information.autorucMedicina;Corbalán R;S/I;98700
dc.issue.numero21
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final2234
dc.pagina.inicio2227
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.revistaCIRCULATION
dc.rightsacceso restringido
dc.subjectmyocardial infarction
dc.subjectischemia
dc.subjectglucose
dc.subjectinsulin
dc.subjectpotassium
dc.subjectcoronary disease
dc.subjectIMMEDIATE ANGIOPLASTY
dc.subjectTHROMBOLYTIC THERAPY
dc.subjectFATTY-ACIDS
dc.subjectISCHEMIA
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleMetabolic modulation of acute myocardial infarction - The ECLA glucose-insulin-potassium pilot trial
dc.typeartículo
dc.volumen98
sipa.codpersvinculados98700
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Metabolic modulation of acute myocardial infarction - The ECLA glucose-insulin-potassium pilot trial.pdf
Size:
3.13 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas